Baidu
map

Heart:肺部超声引导疗法可减少慢性心衰患者急性失代偿事件

2020-06-24 MedSci原创 MedSci原创

LUS指导的治疗降低了慢性HF门诊患者随访期间ADHF的住院率。

心力衰竭(HF)患者肺充血是住院的主要原因。肺部超声(LUS)是识别亚临床肺充血的有用工具。近日,心脏病领域权威杂志Heart上发表了一篇研究文章,研究人员旨在评估了除了体格检查(PE)之外,LUS在HF患者门诊管理中的效用。

在这项随机、多中心、无盲的研究中,研究人员将慢性HF和优化药物治疗的患者随机分为两组:“PE+LUS”组接受PE和LUS,以及“PE only”组。分别根据LUS的结果和PE对利尿疗法进行了调整。该研究的主要终点是在90天随访期间急性失代偿性心力衰竭(ADHF)的住院率降低情况。次要终点是90天随访时NT-proBNP水平、生活质量测试(QLT)和心脏死亡率降低。

该研究共有244例慢性HF和优化药物治疗的患者入选,并随机分为接受PE和LUS的“PE+LUS”组和仅接受PE的“PE only”组。研究期间共发生了37项主要终点事件。“PE+LUS”组在90天时的ADHF住院率显著降低(9.4% vs. 21.4%;相对风险=0.44;95%CI为0.23至0.84;p=0.01),ADHF住院风险降低了56%(p=0.01),需要治疗的患者人数为8.4(95%CI为4.8至34.3)。在第90天,“PE+LUS”组患者的NT-proBNP水平和QLT得分显著降低,而“PE only”组的NT-proBNP水平和QLT得分均升高。两组之间的死亡率没有差异。

由此可见,LUS指导的治疗降低了慢性HF门诊患者随访期间ADHF的住院率。

原始出处:

Claudia Marini.et al.Lung ultrasound-guided therapy reduces acute decompensation events in chronic heart failure.heart.2020.http://dx.doi.org/10.1136/heartjnl-2019-316429

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1769830, encodeId=53641e698303f, content=<a href='/topic/show?id=b3fc92e7516' target=_blank style='color:#2F92EE;'>#超声引导#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92775, encryptionId=b3fc92e7516, topicName=超声引导)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d66e38113145, createdName=guoyibin, createdTime=Mon Jan 11 04:04:35 CST 2021, time=2021-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813481, encodeId=0f151813481f5, content=<a href='/topic/show?id=0ba692e7473' target=_blank style='color:#2F92EE;'>#超声引#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92774, encryptionId=0ba692e7473, topicName=超声引)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Mon Aug 24 04:04:35 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357542, encodeId=a3af135e54218, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jun 26 14:04:35 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373485, encodeId=02ee13e34850e, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Fri Jun 26 14:04:35 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563323, encodeId=4e641563323c0, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Jun 26 14:04:35 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799779, encodeId=13a9e99779c8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230214/f9a4c33015ad4f8c8421eeb2fef26ab3/8f194fc039fc48afa071caaab4eff3ab.jpg, createdBy=98072077561, createdName=牛顿爱吃苹果, createdTime=Thu Jun 25 10:21:16 CST 2020, time=2020-06-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1769830, encodeId=53641e698303f, content=<a href='/topic/show?id=b3fc92e7516' target=_blank style='color:#2F92EE;'>#超声引导#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92775, encryptionId=b3fc92e7516, topicName=超声引导)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d66e38113145, createdName=guoyibin, createdTime=Mon Jan 11 04:04:35 CST 2021, time=2021-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813481, encodeId=0f151813481f5, content=<a href='/topic/show?id=0ba692e7473' target=_blank style='color:#2F92EE;'>#超声引#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92774, encryptionId=0ba692e7473, topicName=超声引)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Mon Aug 24 04:04:35 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357542, encodeId=a3af135e54218, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jun 26 14:04:35 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373485, encodeId=02ee13e34850e, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Fri Jun 26 14:04:35 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563323, encodeId=4e641563323c0, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Jun 26 14:04:35 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799779, encodeId=13a9e99779c8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230214/f9a4c33015ad4f8c8421eeb2fef26ab3/8f194fc039fc48afa071caaab4eff3ab.jpg, createdBy=98072077561, createdName=牛顿爱吃苹果, createdTime=Thu Jun 25 10:21:16 CST 2020, time=2020-06-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1769830, encodeId=53641e698303f, content=<a href='/topic/show?id=b3fc92e7516' target=_blank style='color:#2F92EE;'>#超声引导#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92775, encryptionId=b3fc92e7516, topicName=超声引导)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d66e38113145, createdName=guoyibin, createdTime=Mon Jan 11 04:04:35 CST 2021, time=2021-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813481, encodeId=0f151813481f5, content=<a href='/topic/show?id=0ba692e7473' target=_blank style='color:#2F92EE;'>#超声引#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92774, encryptionId=0ba692e7473, topicName=超声引)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Mon Aug 24 04:04:35 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357542, encodeId=a3af135e54218, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jun 26 14:04:35 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373485, encodeId=02ee13e34850e, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Fri Jun 26 14:04:35 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563323, encodeId=4e641563323c0, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Jun 26 14:04:35 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799779, encodeId=13a9e99779c8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230214/f9a4c33015ad4f8c8421eeb2fef26ab3/8f194fc039fc48afa071caaab4eff3ab.jpg, createdBy=98072077561, createdName=牛顿爱吃苹果, createdTime=Thu Jun 25 10:21:16 CST 2020, time=2020-06-25, status=1, ipAttribution=)]
    2020-06-26 zhaojie88
  4. [GetPortalCommentsPageByObjectIdResponse(id=1769830, encodeId=53641e698303f, content=<a href='/topic/show?id=b3fc92e7516' target=_blank style='color:#2F92EE;'>#超声引导#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92775, encryptionId=b3fc92e7516, topicName=超声引导)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d66e38113145, createdName=guoyibin, createdTime=Mon Jan 11 04:04:35 CST 2021, time=2021-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813481, encodeId=0f151813481f5, content=<a href='/topic/show?id=0ba692e7473' target=_blank style='color:#2F92EE;'>#超声引#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92774, encryptionId=0ba692e7473, topicName=超声引)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Mon Aug 24 04:04:35 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357542, encodeId=a3af135e54218, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jun 26 14:04:35 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373485, encodeId=02ee13e34850e, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Fri Jun 26 14:04:35 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563323, encodeId=4e641563323c0, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Jun 26 14:04:35 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799779, encodeId=13a9e99779c8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230214/f9a4c33015ad4f8c8421eeb2fef26ab3/8f194fc039fc48afa071caaab4eff3ab.jpg, createdBy=98072077561, createdName=牛顿爱吃苹果, createdTime=Thu Jun 25 10:21:16 CST 2020, time=2020-06-25, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1769830, encodeId=53641e698303f, content=<a href='/topic/show?id=b3fc92e7516' target=_blank style='color:#2F92EE;'>#超声引导#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92775, encryptionId=b3fc92e7516, topicName=超声引导)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d66e38113145, createdName=guoyibin, createdTime=Mon Jan 11 04:04:35 CST 2021, time=2021-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813481, encodeId=0f151813481f5, content=<a href='/topic/show?id=0ba692e7473' target=_blank style='color:#2F92EE;'>#超声引#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92774, encryptionId=0ba692e7473, topicName=超声引)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Mon Aug 24 04:04:35 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357542, encodeId=a3af135e54218, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jun 26 14:04:35 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373485, encodeId=02ee13e34850e, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Fri Jun 26 14:04:35 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563323, encodeId=4e641563323c0, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Jun 26 14:04:35 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799779, encodeId=13a9e99779c8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230214/f9a4c33015ad4f8c8421eeb2fef26ab3/8f194fc039fc48afa071caaab4eff3ab.jpg, createdBy=98072077561, createdName=牛顿爱吃苹果, createdTime=Thu Jun 25 10:21:16 CST 2020, time=2020-06-25, status=1, ipAttribution=)]
    2020-06-26 slcumt
  6. [GetPortalCommentsPageByObjectIdResponse(id=1769830, encodeId=53641e698303f, content=<a href='/topic/show?id=b3fc92e7516' target=_blank style='color:#2F92EE;'>#超声引导#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92775, encryptionId=b3fc92e7516, topicName=超声引导)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d66e38113145, createdName=guoyibin, createdTime=Mon Jan 11 04:04:35 CST 2021, time=2021-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1813481, encodeId=0f151813481f5, content=<a href='/topic/show?id=0ba692e7473' target=_blank style='color:#2F92EE;'>#超声引#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92774, encryptionId=0ba692e7473, topicName=超声引)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb182500058, createdName=yuhaisheng_ibp_32061711, createdTime=Mon Aug 24 04:04:35 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357542, encodeId=a3af135e54218, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jun 26 14:04:35 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1373485, encodeId=02ee13e34850e, content=<a href='/topic/show?id=2fd051939ab' target=_blank style='color:#2F92EE;'>#心衰患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51939, encryptionId=2fd051939ab, topicName=心衰患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=467c360, createdName=yuanming7, createdTime=Fri Jun 26 14:04:35 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563323, encodeId=4e641563323c0, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Fri Jun 26 14:04:35 CST 2020, time=2020-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=799779, encodeId=13a9e99779c8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20230214/f9a4c33015ad4f8c8421eeb2fef26ab3/8f194fc039fc48afa071caaab4eff3ab.jpg, createdBy=98072077561, createdName=牛顿爱吃苹果, createdTime=Thu Jun 25 10:21:16 CST 2020, time=2020-06-25, status=1, ipAttribution=)]
    2020-06-25 牛顿爱吃苹果

    学习了

    0

相关资讯

OCC 2020:黄峻教授:慢性心衰药物全新作用机制展露新曙光

心力衰竭(心衰)是多种原因导致心脏结构和/或功能的异常改变,使心室收缩和/或舒张功能发生障碍,从而引起的一组复杂临床综合征,主要表现为呼吸困难、疲乏和液体潴留(肺淤血、体循环淤血及外周水肿)等。根据左

Circulation:补充铁对慢性心衰伴缺铁的患者的骨骼肌能量的影响

补铁可增强慢性心衰(HF)患者的运动能力,但潜在机制尚不明确。铁除了参与血红蛋白(Hb)的合成,还是线粒体酶(以三磷酸腺苷和磷酸肌酸[PCr]的形式产生细胞能量)的重要成分。动态磷磁共振波谱是一种非侵入性的手段,可通过检测运动后PCr恢复的动力学来量化体内肌肉的能量。研究人员推测慢性HF患者静脉铁充盈可增加骨骼肌能量(PCr半恢复时间[PCr t1/2]变短),并对此进行验证。研究人员招募了40位

Kidney int:慢性心衰患者的肾功能可以动态地预测临床结果!

肾功能不全是慢性心力衰竭(CHF)的重要组成部分,但对其单一评估并不能充分反映发生不良的临床结局之前,CHF无临床表现的进展。近期,一项发表在杂志Kidney int上的研究调查例263例稳定型CHF患者的肾小球和肾小管标记物的时间演变过程,并确定了在临床沉默期,患者的特异性进展是否能动态预测临床结果。研究者们确定了临床结果(因心力衰竭住院、心源性死亡、左心室辅助装置置入和心脏移植的复合终点)与标

Lancet Diabetes endo:Neprilysin(脑啡肽酶)抑制,可减缓合并糖尿病的慢性心衰患者的肾功能减退

已证实脑啡肽酶(Neprilysin)抑制对实验性糖尿病有良好的治疗效果。现研究人员对脑啡肽酶抑制对2型糖尿病患者的肾功能的影响进行评估。在随机的、双盲的PATADIGM-HF试验中,在8399位轻中度慢性心衰和收缩功能受限的患者中将沙库比曲/缬沙坦(97mg/103mg 2/日)的效果与依那普利(10mg 2/日)的进行对比。在本次对该试验的二次意向性治疗分析中,研究人员对患者(3784位糖尿病

PLos One:NT-proBNP预测慢性心衰患者两年预后的价值

在慢性心衰患者中使用考虑到利尿钠肽的预测模型,应成为常规临床实践的标准。

NEJM:Vericiguat能减少心衰高危患者的死亡和住院风险(VICTORIA试验)

根据3月28日在ACC.20 / WCC上发表的VICTORIA 3期试验的结果,服用新药Vericoguat的高危心力衰竭(HF)患者的心血管相关死亡和HF相关住院治疗的发生率可能较低,该研究在最新

Baidu
map
Baidu
map
Baidu
map